Beyond conventional therapies: the evolution of targeted agents and immunotherapies in triple-negative breast cancer
Key approaches targeting DNA repair deficiency, immune regulation, oncogenic signaling pathways, and antigen-directed therapies are highlighted, and their clinical development and application are discussed.